Sara Radcliffe, President and CEO of the California Life Sciences Association, discusses where Scott Gottlieb, M.D., is most likely to impact biopharma, and what the industry hopes he will accomplish as the FDA’s new commissioner.

PodcastsResourcesBiopharmaceuticalsClinical trialDrug development (Research and development)Drug research and developmentDrugsHealth care and economicsHealth care facility, manpower, and servicesHealth care organizationsPharmacologyResearch and developmentUnited States Food and Drug Administration
Previous articleNew HIV Vaccine Strategy Could Be Key to Thwarting Virus
Next articleCorbin, Proteorex Partner on USP15 Inhibitors for Neuroinflammatory Disorders